3/ @BrianNosek:
“The big challenge as we see it is that the values that we have for how we think science should operate are not aligned with the culture, the incentives, and the policy landscape for driving how science does operate.”
4/ “It's much easier for me to publish a novel finding than publish a finding saying: Oh yeah, I found that you were right. So why would I conduct a replication if journals don't care about replications, if funders won't fund replications?…”
5/ “…Innovation is the engine of scientific advancement, but the incentive models have gotten so extreme that its innovation at the expense of verification.”
“I think all the incentives on academia are just wrong and perverse. Academia rewards scientists predominantly for the act of publishing a lot of papers in high profile journals like more than anything else that determines success in securing grants, …”
7/ “… in achieving tenure... It's a metric that has come to define professional success in academia. And I think as a result, a lot of scientists are incentivized to produce work that is splashy and attention-grabbing instead of work that's actually rigorous and true.“
8/ this next quote is so good, I’m transcribing the whole thing as an image-
2/ All your interjections in the debate should come as no surprise to anyone -- especially the participants.
In other words, clearly define the rules in advance on what you'll be enforcing, and ideally, you should announce these to the audience at the beginning as well.
3/ Thus, if someone steps out of line for these agreed upon rules and you promptly enforce them, there should be no controversy as this was expected.
A "bad call" is always a problem in any sport, the losing side feels robbed, and even the winning side feels the victory tainted.
2/ For a relevant example-- this study makes direct comparisons on symptomatic ("chest pain") patients ultimately diagnosed AMI (acute myocardial infarction, aka heart attack) vs symptomatic yet diagnosed as not having had an AMI... journals.sagepub.com/doi/full/10.41…
3/ "There were significant decreases in TC, LDL and HDL levels in both STEMI and NSTEMI patients as compared to normal subjects; however, patients with chest pain did not show any significant change in these lipids."
2/ First, be sure to check out this short thread from the lead author, @MaBMortensen.
2 quick notes:
a) While there'll be lots of data appreciated by LDL skepticism, @MaBMortensen maintains LDL-C is still "an important causal RF"
b) Usual epi caveats, etc
3/ Okay, so if you've followed me a while, you know just how incredibly thankful I am of studies that seek to avoid common risks of selection bias (Even if entirely unintended).
This study had the distinct advantage of categorically scooping its population directly...
1/ Reminder: I realize it’s the single hardest concept to get across, but for all these years I have and continue to suggest there’s a crucial case of lipoprotein profiles as often more a reflection of disease than the independent drivers of it. (ie — from 2018 re general👇)
2/ For example, I certainly know so much more on the workings of #LEM* than when I tweeted this from 2018, but does the foundation still hold up… do I think this is more relevant or less? Definitely more!
(*Obligatory mention of @nicknorwitz here and others re coming paper!)
3/ The bottom line is that while the independent causal role of lipoproteins (whether LDLp, sdLDL, oxLDL, glLDL, etc) are well worth examining. We should likewise investigate how *both* lipid profiles and CVD can be downstream of poor lipid metabolism.
2/ They've kindly agreed to provide a coupon code "CITIZEN" for their package to help get both a discount and allow opting in your anonymized data to our OYL anonymous data pool. (Just like we do at our site)
No, there's no $$$ or compensation for us or anything like that...
3/ ... Which might seem confusing since they are technically a competitor given they offer bloodwork as well.
But hello -- @siobhan_huggins and I are *always* game for *everyone* finding what works for them. And seriously, I think this platform is a strong step forward.